CA2155123A1 - Antagonistes du recepteur de fibrinogene - Google Patents

Antagonistes du recepteur de fibrinogene

Info

Publication number
CA2155123A1
CA2155123A1 CA002155123A CA2155123A CA2155123A1 CA 2155123 A1 CA2155123 A1 CA 2155123A1 CA 002155123 A CA002155123 A CA 002155123A CA 2155123 A CA2155123 A CA 2155123A CA 2155123 A1 CA2155123 A1 CA 2155123A1
Authority
CA
Canada
Prior art keywords
alkyl
mmol
mammal
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002155123A
Other languages
English (en)
Inventor
David Alan Claremon
John J. Baldwin
Nigel Liverton
Ben Askew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155123A1 publication Critical patent/CA2155123A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CA002155123A 1993-02-22 1994-02-22 Antagonistes du recepteur de fibrinogene Abandoned CA2155123A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2051793A 1993-02-22 1993-02-22
US020,517 1993-02-22

Publications (1)

Publication Number Publication Date
CA2155123A1 true CA2155123A1 (fr) 1994-09-01

Family

ID=21799049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155123A Abandoned CA2155123A1 (fr) 1993-02-22 1994-02-22 Antagonistes du recepteur de fibrinogene

Country Status (15)

Country Link
EP (1) EP0684823A4 (fr)
JP (1) JP3173792B2 (fr)
KR (1) KR960700722A (fr)
CN (1) CN1118139A (fr)
AU (1) AU680240B2 (fr)
BG (1) BG99863A (fr)
CA (1) CA2155123A1 (fr)
CZ (1) CZ210895A3 (fr)
FI (1) FI953916A (fr)
HU (1) HUT71796A (fr)
NO (1) NO953270L (fr)
NZ (1) NZ262664A (fr)
PL (1) PL310386A1 (fr)
SK (1) SK102495A3 (fr)
WO (1) WO1994018981A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
CA2233204A1 (fr) 1995-09-29 1997-04-03 Joseph A. Jakubowski Composes spiro comme inhibiteurs de l'agregation de plaquettes dependante du fibrinogene
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
WO1997035579A1 (fr) * 1996-03-27 1997-10-02 Merck & Co., Inc. Procede d'inhibition de la formation de caillots
AU3738597A (en) * 1996-07-25 1998-02-20 Biogen, Inc. Molecular model for vla-4 inhibitors
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
JP2001512439A (ja) * 1997-02-06 2001-08-21 メルク エンド カンパニー インコーポレーテッド 線維素原受容体拮抗薬プロドラッグ
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
US6303625B1 (en) * 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
MXPA02000888A (es) * 1999-07-28 2002-07-30 Aventis Pharm Prod Inc Compuestos de oxoazaheterociclilos substituidos.
EP1572682A4 (fr) * 2002-12-20 2008-01-23 Pharmacia Corp Composés de pyrazole acyclique
US20100035756A1 (en) * 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
CA2719288A1 (fr) * 2008-04-04 2009-11-12 Gilead Sciences, Inc. Derives de triazolopyridinone destines a etre utilises comme inhibiteurs de la stearoyl-coa desaturase
WO2010096722A1 (fr) * 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2,3-dihydro-[1,2,4]triazolo[4, 3-a]pyridines utilisées comme inhibiteurs de l'époxyde hydrolase soluble (eh soluble)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
GB8913011D0 (en) * 1989-06-06 1989-07-26 Wellcome Found Anticonvulsant pyrazines
US5166154A (en) * 1989-10-17 1992-11-24 Boehringer Ingelheim Pharmaceuticals, Inc. Imidazo[1,2-a]piperazines
US5278161A (en) * 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors

Also Published As

Publication number Publication date
NO953270L (no) 1995-10-19
BG99863A (en) 1996-02-29
EP0684823A1 (fr) 1995-12-06
PL310386A1 (en) 1995-12-11
KR960700722A (ko) 1996-02-24
HUT71796A (en) 1996-02-28
AU680240B2 (en) 1997-07-24
NO953270D0 (no) 1995-08-21
SK102495A3 (en) 1997-01-08
CZ210895A3 (en) 1996-02-14
FI953916A0 (fi) 1995-08-21
JP3173792B2 (ja) 2001-06-04
CN1118139A (zh) 1996-03-06
WO1994018981A1 (fr) 1994-09-01
JPH08507072A (ja) 1996-07-30
HU9502028D0 (en) 1995-09-28
EP0684823A4 (fr) 1997-07-09
AU6246594A (en) 1994-09-14
NZ262664A (en) 1997-04-24
FI953916A (fi) 1995-08-21

Similar Documents

Publication Publication Date Title
CA2155123A1 (fr) Antagonistes du recepteur de fibrinogene
AU674553B2 (en) Fibrinogen receptor antagonists
AU647618B2 (en) Fibrinogen receptor antagonists
AU712082B2 (en) Fibrinogen receptor antagonists
CA2242877A1 (fr) Antagonistes du recepteur integrine
CA2161787A1 (fr) Antagonistes du recepteur de fibrinogene
EP0714295B1 (fr) Antagonistes du recepteur du fibrinogene
US5340798A (en) Fibrinogen receptor antagonists
US5821241A (en) Fibrinogen receptor antagonists
US5358956A (en) Fibrinogen receptor antagonists
GB2292147A (en) Piperidine derivative fibrinogen receptor antagonists
AU742197B2 (en) Fibrinogen receptor antagonists
US5789421A (en) Fibrinogen receptor antagonist
US5525617A (en) Fibrinogen receptor antagonists
AU702025B2 (en) Fibrinogen receptor antagonist
US5889023A (en) Fibrinogen receptor antagonist
GB2312895A (en) Fibrinogen receptor antagonists
CA2198478A1 (fr) Antagonistes des recepteurs du fibrinogen

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued